Efficacy and safety of ponatinib in heavily pretreated leukemia patients in the PACE trial: 3-year results. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does not ...
Clinical trial data demonstrate that Cavhanza can be taken with or without food, offering patients greater administration convenience.
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...
Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib. Background: The BCR-ABL fusion gene results from the translocation t(9;22). It is the hallmark of chronic ...
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...
(NASDAQ: ARIA) today announced twelve-month follow-up data from the pivotal PACE trial of , its investigational BCR-ABL inhibitor, in heavily pretreated patients with resistant or refractory chronic ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results